Skip to product information
1 of 1

Mouse Anti-Human Siglec-10 Antibody (S-4483)

Mouse Anti-Human Siglec-10 Antibody (S-4483)

Catalog Number: S0B80099 Application: FCM Reactivity: Hu Conjugation: Unconjugated Brand: Starter
Price:
Regular price $100 USD
Regular price Sale price $100 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Mouse
Antigen Siglec-10
Synonyms Sialic acid-binding Ig-like lectin 10; SLG2; SIGLEC10
Location Cell membrane
Accession Q96LC7
Clone Number S-4483
Antibody Type Mouse mAb
Isotype IgG1,k
Application FCM
Reactivity Hu
Purification Protein G
Concentration 2 mg/ml
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer

PBS pH7.4

Stability & Storage

12 months from date of receipt / reconstitution, 2 to 8 °C as supplied

Dilution


application dilution species
FCM 1:200 Hu

Background

Siglec-10 (Sialic acid-binding Ig-like lectin 10) is an inhibitory immune checkpoint receptor primarily expressed on the surface of human myeloid cells, including monocytes, macrophages, and dendritic cells, which plays a critical role in maintaining immune tolerance and preventing excessive inflammation. Structurally characterized by an N-terminal V-set Ig-like domain that specifically recognizes sialic acid residues on glycan chains, Siglec-10 transmits negative regulatory signals upon ligand binding through its cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and ITIM-like sequences, thereby recruiting phosphatases such as SHP-1 and SHP-2 to dampen downstream activating signaling pathways. This receptor is notably involved in distinguishing self from non-self by interacting with "self-associated molecular patterns" (SAMPs), a mechanism that suppresses immune responses against healthy host tissues but can be co-opted by tumors to evade immune surveillance; consequently, blocking the interaction between Siglec-10 and its sialylated ligands has emerged as a promising therapeutic strategy in cancer immunotherapy to reactivate anti-tumor immunity, while its dysfunction is also implicated in various inflammatory disorders and infectious diseases where pathogen mimicry of host glycans exploits this inhibitory pathway.